Genetic defects in B-cell development and their clinical consequences

Journal of Investigational Allergology and Clinical Immunology

Volumn 24, Issue 1, 2014, Pages 6-22

  Abolhassani, H ^a,b   Parvaneh, N ^a   Rezaei, N ^a   Hammarstrom L ^b   Aghamohammadi, A ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

B cell development; Clinical phenotypes; Genetic disorder; Primary antibody deficiencies

Indexed keywords

ACTIVATION INDUCED CYTIDINE DEAMINASE; B CELL ACTIVATING FACTOR RECEPTOR; B CELL LINKER PROTEIN; BIOCHEMICAL MARKER; BRUTON TYROSINE KINASE; CD19 ANTIGEN; CD20 ANTIGEN; CD34 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; CD79B ANTIGEN; CD81 ANTIGEN; COMPLEMENT COMPONENT C3D RECEPTOR; E47 TRANSCRIPTION FACTOR; I KAPPA B KINASE GAMMA; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOGLOBULIN MU CHAIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN; PROTEIN MSH2; RAG PROTEIN; SURROGATE IMMUNOGLOBULIN LIGHT CHAIN; TRANSCRIPTION FACTOR; TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; URACIL DNA GLYCOSIDASE;

ANTIBODY RESPONSE; B LYMPHOCYTE; BACTERIAL INFECTION; BONE MARROW; CELL MATURATION; CHROMOSOME; GENE EXPRESSION; GENE MUTATION; GENETIC DISORDER; HEMATOPOIETIC STEM CELL; HUMAN; HUMORAL IMMUNITY; HYPER IGM SYNDROME; IMMUNE DEFICIENCY; LIVER; LYMPHOID HYPERPLASIA; LYMPHOID ORGAN; NONHUMAN; PHENOTYPE; PNEUMOCYSTIS JIROVECI; REVIEW; SOMATIC HYPERMUTATION; X LINKED AGAMMAGLOBULINEMIA;

B-LYMPHOCYTES; BONE MARROW CELLS; CELL DIFFERENTIATION; HEMATOPOIETIC STEM CELLS; HUMANS; LYMPHOCYTE ACTIVATION;

EID: 84895891017     PISSN: 10189068     EISSN: 16980808     Source Type: Journal    
DOI: None     Document Type: Review

References (219)

1. Bonilla FA, Bernstein IL, Khan DA, Ballas ZK, Chinen J, Frank MM, Kobrynski LJ, Levinson AI, Mazer B, Nelson RP, Jr., Orange JS, Routes JM, Shearer WT, Sorensen RU, American Academy of Allergy A, Immunology, American College of Allergy A, Immunology, Joint Council of Allergy A, Immunology. Practice parameter for the diagnosis and management of primary immunodeficiency. Ann Allergy Asthma Immunol. 2005;94:S1-63.
2. Fried AJ, Bonilla FA. Pathogenesis, diagnosis, and management of primary antibody deficiencies and infections. Clin Microbiol Rev. 2009;22:396-414.
3. Maarschalk-Ellerbroek LJ, Hoepelman IM, Ellerbroek PM. Immunoglobulin treatment in primary antibody deficiency. Int J Antimicrob Agents. 2011;37:396-404.
4. Moise A, Nedelcu FD, Toader MA, Sora SM, Tica A, Ferastraoaru DE, Constantinescu I. Primary immunodeficiencies of the B lymphocyte. J Med Life. 2010;3:60-3.
5. Pan-Hammarstrom Q, Hammarstrom L. Antibody deficiency diseases. Eur J Immunol. 2008;38:327-33.
6. Immunological development and antibody deficiency diseases. Br Med J. 1967;1:320-1.
7. Ballow M. Primary immunodeficiency disorders: antibody deficiency. J Allergy Clin Immunol. 2002;109:581-91.
8. Conley ME, Broides A, Hernandez-Trujillo V, Howard V, Kanegane H, Miyawaki T, Shurtleff SA. Genetic analysis of patients with defects in early B-cell development. Immunol Rev. 2005;203:216-34.
9. Minegishi Y, Rohrer J, Conley ME. Recent progress in the diagnosis and treatment of patients with defects in early B-cell development. Curr Opin Pediatr. 1999;11:528-32.
10. Barr TA, Gray M, Gray D. B cells: programmers of CD4 T cell responses. Infect Disord Drug Targets. 2012;12:222-31.
11. Hardy RR. B-cell commitment: deciding on the players. Curr Opin Immunol. 2003;15:158-65.
12. Abbas A, Lichtman A, Pillai S. Cellular and Molecular Immunology. 7th ed. Philadelphia, PA: Elsevier Saunders; 2012.
13. Conley ME. Early defects in B cell development. Curr Opin Allergy Clin Immunol. 2002;2:517-22.
14. Burrows PD, Cooper MD. B cell development and differentiation. Curr Opin Immunol. 1997;9:239-44.
15. Johnson K, Reddy KL, Singh H. Molecular pathways and mechanisms regulating the recombination of immunoglobulin genes during B-lymphocyte development. Adv Exp Med Biol. 2009;650:133-47.
16. Aghamohammadi A, Lougaris V, Plebani A, Miyawaki T, Durandy A, Hammarström L. Primary immunodeficiency diseases: definition, diagnosis and management. Predominantly antibody deficiency. Heidelberg: Springer; 2008.
17. Bruton OC. Agammaglobulinemia. Pediatrics. 1952;9:722-8.
18. Vetrie D, Vorechovsky I, Sideras P, Holland J, Davies A, Flinter F, Hammarstrom L, Kinnon C, Levinsky R, Bobrow M, et al. The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases. Nature. 1993;361:226-33.
19. Tsukada S, Saffran DC, Rawlings DJ, Parolini O, Allen RC, Klisak I, Sparkes RS, Kubagawa H, Mohandas T, Quan S, et al. Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia. Cell. 1993;72:279-90.
20. Berning AK, Eicher EM, Paul WE, Scher I. Mapping of the X-linked immune deficiency mutation (xid) of CBA/N mice. J Immunol. 1980;124:1875-7.
21. Dobbs AK, Yang T, Farmer D, Kager L, Parolini O, Conley ME. Cutting edge: a hypomorphic mutation in Igbeta (CD79b) in a patient with immunodeficiency and a leaky defect in B cell development. J Immunol. 2007;179:2055-9.
22. Ferrari S, Lougaris V, Caraffi S, Zuntini R, Yang J, Soresina A, Meini A, Cazzola G, Rossi C, Reth M, Plebani A. Mutations of the Igbeta gene cause agammaglobulinemia in man. J Exp Med. 2007;204:2047-51.
23. Ferrari S, Zuntini R, Lougaris V, Soresina A, Sourkova V, Fiorini M, Martino S, Rossi P, Pietrogrande MC, Martire B, Spadaro G, Cardinale F, Cossu F, Pierani P, Quinti I, Rossi C, Plebani A. Molecular analysis of the pre-BCR complex in a large cohort of patients affected by autosomal-recessive agammaglobulinemia. Genes Immun. 2007;8:325-33.
24. Minegishi Y, Rohrer J, Coustan-Smith E, Lederman HM, Pappu R, Campana D, Chan AC, Conley ME. An essential role for BLNK in human B cell development. Science. 1999;286:1954-7.
25. Minegishi Y, Coustan-Smith E, Wang YH, Cooper MD, Campana D, Conley ME. Mutations in the human lambda5/14.1 gene result in B cell deficiency and agammaglobulinemia. J Exp Med. 1998;187:71-7.
26. Wang Y, Kanegane H, Sanal O, Tezcan I, Ersoy F, Futatani T, Miyawaki T. Novel Igalpha (CD79a) gene mutation in a Turkish patient with B cell-deficient agammaglobulinemia. Am J Med Genet. 2002;108:333-6.
27. Yel L, Minegishi Y, Coustan-Smith E, Buckley RH, Trubel H, Pachman LM, Kitchingman GR, Campana D, Rohrer J, Conley ME. Mutations in the mu heavy-chain gene in patients with agammaglobulinemia. N Engl J Med. 1996;335:1486-93.
28. Aghamohammadi A, Fiorini M, Moin M, Parvaneh N, Teimourian S, Yeganeh M, Goffi F, Kanegane H, Amirzargar AA, Pourpak Z, Rezaei N, Salavati A, Pouladi N, Abdollahzade S, Notarangelo LD, Miyawaki T, Plebani A. Clinical, immunological and molecular characteristics of 37 Iranian patients with X-linked agammaglobulinemia. Int Arch Allergy Immunol. 2006;141:408-14.
29. Moin M, Aghamohammadi A, Farhoudi A, Pourpak Z, Rezaei N, Movahedi M, Gharagozlou M, Ghazi BM, Zahed A, Abolmaali K, Mahmoudi M, Emami L, Bashashati M. X-linked agammaglobulinemia: a survey of 33 Iranian patients. Immunol Invest. 2004;33:81-93.
30. Aghamohammadi A, Moin M, Farhoudi A, Rezaei N, Pourpak Z, Movahedi M, Gharagozlou M, Nabavi M, Shahrokhi A. Efficacy of intravenous immunoglobulin on the prevention of pneumonia in patients with agammaglobulinemia. FEMS Immunol Med Microbiol. 2004;40:113-8.
31. Cronin FE, Jiang M, Abbas AK, Grupp SA. Role of mu heavy chain in B cell development. I. Blocked B cell maturation but complete allelic exclusion in the absence of Ig alpha/beta. J Immunol. 1998;161:252-9.
32. Kim JH, Rutan JA, Vilen BJ. The transmembrane tyrosine of micro-heavy chain is required for BCR destabilization and entry of antigen into clathrin-coated vesicles. Int Immunol. 2007;19:1403-12.
33. de la Morena M, Haire RN, Ohta Y, Nelson RP, Litman RT, Day NK, Good RA, Litman GW. Predominance of sterile immunoglobulin transcripts in a female phenotypically resembling Bruton's agammaglobulinemia. Eur J Immunol. 1995;25:809-15.
34. Conley ME, Sweinberg SK. Females with a disorder phenotypically identical to X-linked agammaglobulinemia. J Clin Immunol. 1992;12:139-43.
35. Lopez Granados E, Porpiglia AS, Hogan MB, Matamoros N, Krasovec S, Pignata C, Smith CI, Hammarstrom L, Bjorkander J, Belohradsky BH, Casariego GF, Garcia Rodriguez MC, Conley ME. Clinical and molecular analysis of patients with defects in micro heavy chain gene. J Clin Invest. 2002;110:1029-35.
36. Kinoshita K, Yamagata T, Nozaki Y, Sugiyama M, Ikoma S, Funauchi M, Kanamaru A. Mu-heavy chain disease associated with systemic amyloidosis. Hematology. 2004;9:135-7.
37. Iwasaki T, Hamano T, Kobayashi K, Kakishita E. A case of muheavy chain disease: combined features of mu-chain disease and macroglobulinemia. Int J Hematol. 1997;66:359-65.
38. Mohammadzadeh I, Yeganeh M, Aghamohammadi A, Parvaneh N, Behniafard N, Abolhassani H, Tabassomi F, Hemmat M, Kanegane H, Miyawaki T, Ohara O, Rezaei N. Severe primary antibody deficiency due to a novel mutation of mu heavy chain. J Investig Allergol Clin Immunol. 2012;22:78-9.
39. Tamura A, Yamashiro A, Mizutani F, Oita T, Maeda A, Takahashi T. [Immunochemical properties of free mu-chain protein in a patient with mu-heavy chain disease]. Rinsho Byori. 2003;51:847-51.
40. Harfst E, Andersson J, Grawunder U, Ceredig R, Rolink AG. Homeostatic and functional analysis of mature B cells in lambda5-deficient mice. Immunol Lett. 2005;101:173-84.
41. Miyazaki T, Kato I, Takeshita S, Karasuyama H, Kudo A. Lambda5 is required for rearrangement of the Ig kappa light chain gene in pro-B cell lines. Int Immunol. 1999;11:1195-202.
42. Parker MJ, Licence S, Erlandsson L, Galler GR, Chakalova L, Osborne CS, Morgan G, Fraser P, Jumaa H, Winkler TH, Skok J, Martensson IL. The pre-B-cell receptor induces silencing of VpreB and lambda5 transcription. EMBO J. 2005;24:3895-905.
43. Martensson A, Xie XQ, Persson C, Holm M, Grundstrom T, Martensson IL. PEBP2 and c-myb sites crucial for lambda5 core enhancer activity in pre-B cells. Eur J Immunol. 2001;31:3165-74.
44. Ohnishi K, Melchers F. The nonimmunoglobulin portion of lambda5 mediates cell-autonomous pre-B cell receptor signaling. Nat Immunol. 2003;4:849-56.
45. Ferrari S, Zuntini R, Lougaris V, Soresina A, Sourková V, Fiorini M, Martino S, Rossi P, Pietrogrande M, Martire B, Spadaro G, Cardinale F, Cossu F, Pierani P, Quinti I, Rossi C, Plebani A. Molecular analysis of the pre-BCR complex in a large cohort of patients affected by autosomal-recessive agammaglobulinemia. Genes Immun. 2007;8:325-33.
46. Hashimoto S, Chiorazzi N, Gregersen PK. Alternative splicing of CD79a (Ig-alpha/mb-1) and CD79b (Ig-beta/B29) RNA transcripts in human B cells. Mol Immunol. 1995;32:651-9.
47. Wang LD, Clark MR. Igalpha: B all that you can B. J Clin Invest. 1999;104:1011-2.
48. Benlagha K, Guglielmi P, Cooper MD, Lassoued K. Modifications of Igalpha and Igbeta expression as a function of B lineage differentiation. J Biol Chem. 1999;274:19389-96.
49. Shulzhenko N, Morgun A, Matzinger P. Spontaneous mutation in the Cd79b gene leads to a block in B-lymphocyte development at the C' (early pre-B) stage. Genes Immun. 2009;10:722-6.
50. Minegishi Y, Coustan-Smith E, Rapalus L, Ersoy F, Campana D, Conley ME. Mutations in Igalpha (CD79a) result in a complete block in B-cell development. J Clin Invest. 1999;104:1115-21.
51. Lougaris V, Ferrari S, Plebani A. Ig beta deficiency in humans. Curr Opin Allergy Clin Immunol. 2008;8:515-9.
52. Chiu CW, Dalton M, Ishiai M, Kurosaki T, Chan AC. BLNK: molecular scaffolding through 'cis'-mediated organization of signaling proteins. EMBO J. 2002;21:6461-72.
53. Miyazaki A, Yogosawa S, Murakami A, Kitamura D. Identification of CMTM7 as a transmembrane linker of BLNK and the B-cell receptor. PLoS One. 2012;7:e31829.
54. Vendel AC, Calemine-Fenaux J, Izrael-Tomasevic A, Chauhan V, Arnott D, Eaton DL. B and T lymphocyte attenuator regulates B cell receptor signaling by targeting Syk and BLNK. J Immunol. 2009;182:1509-17.
55. Imamura Y, Oda A, Katahira T, Bundo K, Pike KA, Ratcliffe MJ, Kitamura D. BLNK binds active H-Ras to promote B cell receptor-mediated capping and ERK activation. J Biol Chem. 2009;284:9804-13.
56. Taguchi T, Kiyokawa N, Takenouch H, Matsui J, Tang WR, Nakajima H, Suzuki K, Shiozawa Y, Saito M, Katagiri YU, Takahashi T, Karasuyama H, Matsuo Y, Okita H, Fujimoto J. Deficiency of BLNK hampers PLC-gamma2 phosphorylation and Ca2+ influx induced by the pre-B-cell receptor in human pre-B cells. Immunology. 2004;112:575-82.
57. Gupta N, Delrow J, Drawid A, Sengupta AM, Fan G, Gelinas C. Repression of B-cell linker (BLNK) and B-cell adaptor for phosphoinositide 3-kinase (BCAP) is important for lymphocyte transformation by rel proteins. Cancer Res. 2008;68:808-14.
58. Tsukada S, Baba Y, Watanabe D. Btk and BLNK in B cell development. Adv Immunol. 2001;77:123-62.
59. Baba Y, Hashimoto S, Matsushita M, Watanabe D, Kishimoto T, Kurosaki T, Tsukada S. BLNK mediates Syk-dependent Btk activation. Proc Natl Acad Sci U S A. 2001;98:2582-6.
60. Vanhaesebroeck B, Stephens L, Hawkins P. PI3K signalling: the path to discovery and understanding. Nat Rev Mol Cell Biol. 2012;13:195-203.
61. Ma Q, Jones D, Borghesani PR, Segal RA, Nagasawa T, Kishimoto T, Bronson RT, Springer TA. Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4-and SDF-1-deficient mice. Proc Natl Acad Sci U S A. 1998;95:9448-53.
62. Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61-70.
63. Conley ME, Dobbs AK, Quintana AM, Bosompem A, Wang YD, Coustan-Smith E, Smith AM, Perez EE, Murray PJ. Agammaglobulinemia and absent B lineage cells in a patient lacking the p85alpha subunit of PI3K. J Exp Med. 2012;209:463-70.
64. Kenter AL. Class-switch recombination: after the dawn of AID. Curr Opin Immunol. 2003;15:190-8.
65. Gulino AV, Notarangelo LD. Hyper IgM syndromes. Curr Opin Rheumatol. 2003;15:422-9.
66. Durandy A, Revy P, Fischer A. Human models of inherited immunoglobulin class switch recombination and somatic hypermutation defects (hyper-IgM syndromes). Adv Immunol. 2004;82:295-330.
67. Lee WI, Torgerson TR, Schumacher MJ, Yel L, Zhu Q, Ochs HD. Molecular analysis of a large cohort of patients with the hyper immunoglobulin M (IgM) syndrome. Blood. 2005;105:1881-90.
68. Davies EG, Thrasher AJ. Update on the hyper immunoglobulin M syndromes. Br J Haematol. 2010;149:167-80.
69. Durandy A, Kracker S. Immunoglobulin class-switch recombination deficiencies. Arthritis Res Ther. 2012;14:218.
70. Ma DY, Clark EA. The role of CD40 and CD154/CD40L in dendritic cells. Semin Immunol. 2009;21:265-72.
71. Clark EA, Ledbetter JA. How B and T cells talk to each other. Nature. 1994;367:425-8.
72. van Kooten C, Banchereau J. CD40-CD40 ligand. J Leukoc Biol. 2000;67:2-17.
73. Conley ME, Dobbs AK, Farmer DM, Kilic S, Paris K, Grigoriadou S, Coustan-Smith E, Howard V, Campana D. Primary B cell immunodeficiencies: comparisons and contrasts. Annu Rev Immunol. 2009;27:199-227.
74. Allen RC, Armitage RJ, Conley ME, Rosenblatt H, Jenkins NA, Copeland NG, Bedell MA, Edelhoff S, Disteche CM, Simoneaux DK, et al. CD40 ligand gene defects responsible for X-linked hyper-IgM syndrome. Science. 1993;259:990-3.
75. Aruffo A, Farrington M, Hollenbaugh D, Li X, Milatovich A, Nonoyama S, Bajorath J, Grosmaire LS, Stenkamp R, Neubauer M, et al. The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome. Cell. 1993;72:291-300.
76. DiSanto JP, Bonnefoy JY, Gauchat JF, Fischer A, de Saint Basile G. CD40 ligand mutations in x-linked immunodeficiency with hyper-IgM. Nature. 1993;361:541-3.
77. Fuleihan R, Ramesh N, Loh R, Jabara H, Rosen RS, Chatila T, Fu SM, Stamenkovic I, Geha RS. Defective expression of the CD40 ligand in X chromosome-linked immunoglobulin deficiency with normal or elevated IgM. Proc Natl Acad Sci U S A. 1993;90:2170-3.
78. Korthauer U, Graf D, Mages HW, Briere F, Padayachee M, Malcolm S, Ugazio AG, Notarangelo LD, Levinsky RJ, Kroczek RA. Defective expression of T-cell CD40 ligand causes X-linked immunodeficiency with hyper-IgM. Nature. 1993;361:539-41.
79. Noelle RJ, Roy M, Shepherd DM, Stamenkovic I, Ledbetter JA, Aruffo A. A 39-kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells. Proc Natl Acad Sci U S A. 1992;89:6550-4.
80. Garside P, Ingulli E, Merica RR, Johnson JG, Noelle RJ, Jenkins MK. Visualization of specific B and T lymphocyte interactions in the lymph node. Science. 1998;281:96-9.
81. Calame KL, Lin KI, Tunyaplin C. Regulatory mechanisms that determine the development and function of plasma cells. Annu Rev Immunol. 2003;21:205-30.
82. Rickert RC, Jellusova J, Miletic AV. Signaling by the tumor necrosis factor receptor superfamily in B-cell biology and disease. Immunol Rev. 2011;244:115-33.
83. Levy J, Espanol-Boren T, Thomas C, Fischer A, Tovo P, Bordigoni P, Resnick I, Fasth A, Baer M, Gomez L, Sanders EA, Tabone MD, Plantaz D, Etzioni A, Monafo V, Abinun M, Hammarstrom L, Abrahamsen T, Jones A, Finn A, Klemola T, DeVries E, Sanal O, Peitsch MC, Notarangelo LD. Clinical spectrum of X-linked hyper-IgM syndrome. J Pediatr. 1997;131:47-54.
84. Ameratunga R, Lederman HM, Sullivan KE, Ochs HD, Seyama K, French JK, Prestidge R, Marbrook J, Fanslow WC, Winkelstein JA. Defective antigen-induced lymphocyte proliferation in the X-linked hyper-IgM syndrome. J Pediatr. 1997;131:147-50.
85. Agematsu K, Nagumo H, Shinozaki K, Hokibara S, Yasui K, Terada K, Kawamura N, Toba T, Nonoyama S, Ochs HD, Komiyama A. Absence of IgD-CD27(+) memory B cell population in X-linked hyper-IgM syndrome. J Clin Invest. 1998;102:853-60.
86. Winkelstein JA, Marino MC, Ochs H, Fuleihan R, Scholl PR, Geha R, Stiehm ER, Conley ME. The X-linked hyper-IgM syndrome: clinical and immunologic features of 79 patients. Medicine (Baltimore). 2003;82:373-84.
87. Aghamohammadi A, Parvaneh N, Rezaei N, Moazzami K, Kashef S, Abolhassani H, Imanzadeh A, Mohammadi J, Hammarstrom L. Clinical and laboratory findings in hyper-IgM syndrome with novel CD40L and AICDA mutations. J Clin Immunol. 2009;29:769-76.
88. DeKruyff RH, Gieni RS, Umetsu DT. Antigen-driven but not lipopolysaccharide-driven IL-12 production in macrophages requires triggering of CD40. J Immunol. 1997;158:359-66.
89. Hayashi T, Rao SP, Meylan PR, Kornbluth RS, Catanzaro A. Role of CD40 ligand in Mycobacterium avium infection. Infect Immun. 1999;67:3558-65.
90. Leone V, Tommasini A, Andolina M, Runti G, De Vonderweid U, Campello C, Notarangelo LD, Ventura A. Elective bone marrow transplantation in a child with X-linked hyper-IgM syndrome presenting with acute respiratory distress syndrome. Bone Marrow Transplant. 2002;30:49-52.
91. Duplantier JE, Seyama K, Day NK, Hitchcock R, Nelson RP, Jr., Ochs HD, Haraguchi S, Klemperer MR, Good RA. Immunologic reconstitution following bone marrow transplantation for X-linked hyper IgM syndrome. Clin Immunol. 2001;98:313-8.
92. Ferrari S, Giliani S, Insalaco A, Al-Ghonaium A, Soresina AR, Loubser M, Avanzini MA, Marconi M, Badolato R, Ugazio AG, Levy Y, Catalan N, Durandy A, Tbakhi A, Notarangelo LD, Plebani A. Mutations of CD40 gene cause an autosomal recessive form of immunodeficiency with hyper IgM. Proc Natl Acad Sci U S A. 2001;98:12614-9.
93. Lougaris V, Badolato R, Ferrari S, Plebani A. Hyper immunoglobulin M syndrome due to CD40 deficiency: clinical, molecular, and immunological features. Immunol Rev. 2005;203:48-66.
94. Zonana J, Elder ME, Schneider LC, Orlow SJ, Moss C, Golabi M, Shapira SK, Farndon PA, Wara DW, Emmal SA, Ferguson BM. A novel X-linked disorder of immune deficiency and hypohidrotic ectodermal dysplasia is allelic to incontinentia pigmenti and due to mutations in IKK-gamma (NEMO). Am J Hum Genet. 2000;67:1555-62.
95. Jain A, Ma CA, Liu S, Brown M, Cohen J, Strober W. Specific missense mutations in NEMO result in hyper-IgM syndrome with hypohydrotic ectodermal dysplasia. Nat Immunol. 2001;2:223-8.
96. Doffinger R, Smahi A, Bessia C, Geissmann F, Feinberg J, Durandy A, Bodemer C, Kenwrick S, Dupuis-Girod S, Blanche S, Wood P, Rabia SH, Headon DJ, Overbeek PA, Le Deist F, Holland SM, Belani K, Kumararatne DS, Fischer A, Shapiro R, Conley ME, Reimund E, Kalhoff H, Abinun M, Munnich A, Israel A, Courtois G, Casanova JL. X-linked anhidrotic ectodermal dysplasia with immunodeficiency is caused by impaired NFkappaB signaling. Nat Genet. 2001;27:277-85.
97. Kim S, La Motte-Mohs RN, Rudolph D, Zuniga-Pflucker JC, Mak TW. The role of nuclear factor-kappaB essential modulator (NEMO) in B cell development and survival. Proc Natl Acad Sci U S A. 2003;100:1203-8.
98. Smahi A, Courtois G, Rabia SH, Doffinger R, Bodemer C, Munnich A, Casanova JL, Israel A. The NF-kappaB signalling pathway in human diseases: from incontinentia pigmenti to ectodermal dysplasias and immune-deficiency syndromes. Hum Mol Genet. 2002;11:2371-5.
99. Orange JS, Brodeur SR, Jain A, Bonilla FA, Schneider LC, Kretschmer R, Nurko S, Rasmussen WL, Kohler JR, Gellis SE, Ferguson BM, Strominger JL, Zonana J, Ramesh N, Ballas ZK, Geha RS. Deficient natural killer cell cytotoxicity in patients with IKK-gamma/NEMO mutations. J Clin Invest. 2002;109:1501-9.
100. Callard RE, Smith SH, Herbert J, Morgan G, Padayachee M, Lederman S, Chess L, Kroczek RA, Fanslow WC, Armitage RJ. CD40 ligand (CD40L) expression and B cell function in agammaglobulinemia with normal or elevated levels of IgM (HIM). Comparison of X-linked, autosomal recessive, and non-X-linked forms of the disease, and obligate carriers. J Immunol. 1994;153:3295-306.
101. Conley ME, Larche M, Bonagura VR, Lawton AR, 3rd, Buckley RH, Fu SM, Coustan-Smith E, Herrod HG, Campana D. Hyper IgM syndrome associated with defective CD40-mediated B cell activation. J Clin Invest. 1994;94:1404-9.
102. Durandy A, Hivroz C, Mazerolles F, Schiff C, Bernard F, Jouanguy E, Revy P, DiSanto JP, Gauchat JF, Bonnefoy JY, Casanova JL, Fischer A. Abnormal CD40-mediated activation pathway in B lymphocytes from patients with hyper-IgM syndrome and normal CD40 ligand expression. J Immunol. 1997;158:2576-84
103. Revy P, Muto T, Levy Y, Geissmann F, Plebani A, Sanal O, Catalan N, Forveille M, Dufourcq-Labelouse R, Gennery A, Tezcan I, Ersoy F, Kayserili H, Ugazio AG, Brousse N, Muramatsu M, Notarangelo LD, Kinoshita K, Honjo T, Fischer A, Durandy A. Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the Hyper-IgM syndrome (HIGM2). Cell. 2000;102:565-75.
104. Quartier P, Bustamante J, Sanal O, Plebani A, Debre M, Deville A, Litzman J, Levy J, Fermand JP, Lane P, Horneff G, Aksu G, Yalcin I, Davies G, Tezcan I, Ersoy F, Catalan N, Imai K, Fischer A, Durandy A. Clinical, immunologic and genetic analysis of 29 patients with autosomal recessive hyper-IgM syndrome due to Activation-Induced Cytidine Deaminase deficiency. Clin Immunol. 2004;110:22-9.
105. Erdos M, Durandy A, Marodi L. Genetically acquired classswitch recombination defects: the multi-faced hyper-IgM syndrome. Immunol Lett. 2005;97:1-6.
106. Minegishi Y, Lavoie A, Cunningham-Rundles C, Bedard PM, Hebert J, Cote L, Dan K, Sedlak D, Buckley RH, Fischer A, Durandy A, Conley ME. Mutations in activation-induced cytidine deaminase in patients with hyper IgM syndrome. Clin Immunol. 2000;97:203-10.
107. Hase K, Takahashi D, Ebisawa M, Kawano S, Itoh K, Ohno H. Activation-induced cytidine deaminase deficiency causes organ-specific autoimmune disease. PLoS One. 2008;3:e3033.
108. Ta VT, Nagaoka H, Catalan N, Durandy A, Fischer A, Imai K, Nonoyama S, Tashiro J, Ikegawa M, Ito S, Kinoshita K, Muramatsu M, Honjo T. AID mutant analyses indicate requirement for class-switch-specific cofactors. Nat Immunol. 2003;4:843-8.
109. Durandy A, Revy P, Imai K, Fischer A. Hyper-immunoglobulin M syndromes caused by intrinsic B-lymphocyte defects. Immunol Rev. 2005;203:67-79.
110. Kasahara Y, Kaneko H, Fukao T, Terada T, Asano T, Kasahara K, Kondo N. Hyper-IgM syndrome with putative dominant negative mutation in activation-induced cytidine deaminase. J Allergy Clin Immunol. 2003;112:755-60.
111. Imai K, Zhu Y, Revy P, Morio T, Mizutani S, Fischer A, Nonoyama S, Durandy A. Analysis of class switch recombination and somatic hypermutation in patients affected with autosomal dominant hyper-IgM syndrome type 2. Clin Immunol. 2005;115:277-85.
112. Imai K, Slupphaug G, Lee WI, Revy P, Nonoyama S, Catalan N, Yel L, Forveille M, Kavli B, Krokan HE, Ochs HD, Fischer A, Durandy A. Human uracil-DNA glycosylase deficiency associated with profoundly impaired immunoglobulin classswitch recombination. Nat Immunol. 2003;4:1023-8.
113. Nilsen H, Stamp G, Andersen S, Hrivnak G, Krokan HE, Lindahl T, Barnes DE. Gene-targeted mice lacking the Ung uracil-DNA glycosylase develop B-cell lymphomas. Oncogene. 2003;22:5381-6.
114. Kadyrov FA, Dzantiev L, Constantin N, Modrich P. Endonucleolytic function of MutLalpha in human mismatch repair. Cell. 2006;126:297-308.
115. Peron S, Metin A, Gardes P, Alyanakian MA, Sheridan E, Kratz CP, Fischer A, Durandy A. Human PMS2 deficiency is associated with impaired immunoglobulin class switch recombination. J Exp Med. 2008;205:2465-72.
116. Shlomchik MJ, Weisel F. Germinal center selection and the development of memory B and plasma cells. Immunol Rev. 2012;247:52-63.
117. Meffre E. The establishment of early B cell tolerance in humans: lessons from primary immunodeficiency diseases. Ann N Y Acad Sci. 2011;1246:1-10.
118. Montecino-Rodriguez E, Dorshkind K. B-1 B cell development in the fetus and adult. Immunity. 2012;36:13-21.
119. Aghamohammadi A, Abolhassani H, Moazzami K, Parvaneh N, Rezaei N. Correlation between common variable immunodeficiency clinical phenotypes and parental consanguinity in children and adults. J Investig Allergol Clin Immunol. 2010;20:372-9.
120. Aghamohammadi A, Parvaneh N, Rezaei N. Common variable immunodeficiency: a heterogeneous group needs further subclassification. Expert Rev Clin Immunol. 2009;5:629-31.
121. Morio T. [Common variable immunodeficiency: an update on etiology, pathophysiology, and classification]. Nihon Rinsho Meneki Gakkai Kaishi. 2012;35:14-22. Japanese.
122. Salzer U, Unger S, Warnatz K. Common variable immunodeficiency (CVID): exploring the multiple dimensions of a heterogeneous disease. Ann N Y Acad Sci. 2012;1250:41-9.
123. Aghamohammadi A, Mohammadi J, Parvaneh N, Rezaei N, Moin M, Espanol T, Hammarstrom L. Progression of selective IgA deficiency to common variable immunodeficiency. Int Arch Allergy Immunol. 2008;147:87-92.
124. Park JH, Resnick ES, Cunningham-Rundles C. Perspectives on common variable immune deficiency. Ann N Y Acad Sci. 2011;1246:41-9.
125. McHeyzer-Williams M, Okitsu S, Wang N, McHeyzer-Williams L. Molecular programming of B cell memory. Nat Rev Immunol. 2012;12:24-34.
126. Simpson TR, Quezada SA, Allison JP. Regulation of CD4 T cell activation and effector function by inducible costimulator (ICOS). Curr Opin Immunol. 2010;22:326-32.
127. Yong PF, Salzer U, Grimbacher B. The role of costimulation in antibody deficiencies: ICOS and common variable immunodeficiency. Immunol Rev. 2009;229:101-13.
128. Sharpe AH. Mechanisms of costimulation. Immunol Rev. 2009;229:5-11.
129. Garapati VP, Lefranc MP. IMGT Colliers de Perles and IgSF domain standardization for T cell costimulatory activatory (CD28, ICOS) and inhibitory (CTLA4, PDCD1 and BTLA) receptors. Dev Comp Immunol. 2007;31:1050-72.
130. Moser B, Schaerli P, Loetscher P. CXCR5(+) T cells: follicular homing takes center stage in T-helper-cell responses. Trends Immunol. 2002;23:250-4.
131. Grimbacher B, Hutloff A, Schlesier M, Glocker E, Warnatz K, Drager R, Eibel H, Fischer B, Schaffer AA, Mages HW, Kroczek RA, Peter HH. Homozygous loss of ICOS is associated with adult-onset common variable immunodeficiency. Nat Immunol. 2003;4:261-8.
132. Grimbacher B, Warnatz K, Peter HH. The immunological synapse for B-cell memory: the role of the ICOS and its ligand for the longevity of humoral immunity. Curr Opin Allergy Clin Immunol. 2003;3:409-19.
133. Lee WI, Zhu Q, Gambineri E, Jin Y, Welcher AA, Ochs HD. Inducible CO-stimulator molecule, a candidate gene for defective isotype switching, is normal in patients with hyper IgM syndrome of unknown molecular diagnosis. J Allergy Clin Immunol. 2003;112:958-64.
134. Warnatz K, Salzer U, Rizzi M, Fischer B, Gutenberger S, Bohm J, Kienzler AK, Pan-Hammarstrom Q, Hammarstrom L, Rakhmanov M, Schlesier M, Grimbacher B, Peter HH, Eibel H. B-cell activating factor receptor deficiency is associated with an adult-onset antibody deficiency syndrome in humans. Proc Natl Acad Sci U S A. 2009;106:13945-50.
135. Warnatz K, Bossaller L, Salzer U, Skrabl-Baumgartner A, Schwinger W, van der Burg M, van Dongen JJ, Orlowska-Volk M, Knoth R, Durandy A, Draeger R, Schlesier M, Peter HH, Grimbacher B. Human ICOS deficiency abrogates the germinal center reaction and provides a monogenic model for common variable immunodeficiency. Blood. 2006;107:3045-52.
136. Takahashi N, Matsumoto K, Saito H, Nanki T, Miyasaka N, Kobata T, Azuma M, Lee SK, Mizutani S, Morio T. Impaired CD4 and CD8 effector function and decreased memory T cell populations in ICOS-deficient patients. J Immunol. 2009;182:5515-27.
137. Salzer U, Maul-Pavicic A, Cunningham-Rundles C, Urschel S, Belohradsky BH, Litzman J, Holm A, Franco JL, Plebani A, Hammarstrom L, Skrabl A, Schwinger W, Grimbacher B. ICOS deficiency in patients with common variable immunodeficiency. Clin Immunol. 2004;113:234-40.
138. Ohm-Laursen L, Schjebel L, Jacobsen K, Permin H, Svejgaard A, Barington T. Normal ICOS, ICOSL and AID alleles in Danish patients with common variable immunodeficiency. Scand J Immunol. 2005;61:566-74.
139. Richter G, Burdach S. ICOS: a new costimulatory ligand/ receptor pair and its role in T-cell activion. Onkologie. 2004;27:91-5.
140. Yong PF, Thaventhiran JE, Grimbacher B. "A rose is a rose is a rose, " but CVID is Not CVID common variable immune deficiency (CVID), what do we know in 2011? Adv Immunol. 2011;111:47-107.
141. Coyle AJ, Gutierrez-Ramos JC. The role of ICOS and other costimulatory molecules in allergy and asthma. Springer Semin Immunopathol. 2004;25:349-59.
142. Yong PF, Tarzi M, Chua I, Grimbacher B, Chee R. Common variable immunodeficiency: an update on etiology and management. Immunol Allergy Clin North Am. 2008;28:367-86, ix-x.
143. Tsubata T. Role of inhibitory BCR co-receptors in immunity. Infect Disord Drug Targets. 2012;12:181-90.
144. Carter RH, Fearon DT. Pillars Article: CD19: Lowering the threshold for antigen receptor stimulation of B lymphocytes. Science, 1992. 256: 105-107. J Immunol. 2010;184:2233-5.
145. Neumann C, Grimbacher B. [Molecular basis of common variable immunodeficiency]. Dtsch Med Wochenschr. 2007;132:885-7. German.
146. Haas KM, Tedder TF. Role of the CD19 and CD21/35 receptor complex in innate immunity, host defense and autoimmunity. Adv Exp Med Biol. 2005;560:125-39.
147. Poe JC, Minard-Colin V, Kountikov EI, Haas KM, Tedder TF. A c-Myc and surface CD19 signaling amplification loop promotes B cell lymphoma development and progression in mice. J Immunol. 2012;189:2318-25.
148. Chung EY, Psathas JN, Yu D, Li Y, Weiss MJ, Thomas-Tikhonenko A. CD19 is a major B cell receptor-independent activator of MYC-driven B-lymphomagenesis. J Clin Invest. 2012;122:2257-66.
149. van Zelm MC, Smet J, Adams B, Mascart F, Schandene L, Janssen F, Ferster A, Kuo CC, Levy S, van Dongen JJ, van der Burg M. CD81 gene defect in humans disrupts CD19 complex formation and leads to antibody deficiency. J Clin Invest. 2010;120:1265-74.
150. Gauld SB, Dal Porto JM, Cambier JC. B cell antigen receptor signaling: roles in cell development and disease. Science. 2002;296:1641-2.
151. Tsitsikov EN, Gutierrez-Ramos JC, Geha RS. Impaired CD19 expression and signaling, enhanced antibody response to type II T independent antigen and reduction of B-1 cells in CD81-deficient mice. Proc Natl Acad Sci U S A. 1997;94:10844-9.
152. van Zelm MC, Reisli I, van der Burg M, Castano D, van Noesel CJ, van Tol MJ, Woellner C, Grimbacher B, Patino PJ, van Dongen JJ, Franco JL. An antibody-deficiency syndrome due to mutations in the CD19 gene. N Engl J Med. 2006;354:1901-12.
153. Kanegane H, Agematsu K, Futatani T, Sira MM, Suga K, Sekiguchi T, van Zelm MC, Miyawaki T. Novel mutations in a Japanese patient with CD19 deficiency. Genes Immun. 2007;8:663-70.
154. Vince N, Boutboul D, Mouillot G, Just N, Peralta M, Casanova JL, Conley ME, Bories JC, Oksenhendler E, Malphettes M, Fieschi C, Group DS. Defects in the CD19 complex predispose to glomerulonephritis, as well as IgG1 subclass deficiency. J Allergy Clin Immunol. 2011;127:538-41 e1-5.
155. van Zelm MC, Smet J, van der Burg M, Ferster A, Le PQ, Schandene L, van Dongen JJ, Mascart F. Antibody deficiency due to a missense mutation in CD19 demonstrates the importance of the conserved tryptophan 41 in immunoglobulin superfamily domain formation. Hum Mol Genet. 2011;20:1854-63.
156. Miyazaki T, Muller U, Campbell KS. Normal development but differentially altered proliferative responses of lymphocytes in mice lacking CD81. EMBO J. 1997;16:4217-25.
157. Sanyal M, Fernandez R, Levy S. Enhanced B cell activation in the absence of CD81. Int Immunol. 2009;21:1225-37.
158. Maecker HT, Do MS, Levy S. CD81 on B cells promotes interleukin 4 secretion and antibody production during T helper type 2 immune responses. Proc Natl Acad Sci U S A. 1998;95:2458-62.
159. Luo RF, Zhao S, Tibshirani R, Myklebust JH, Sanyal M, Fernandez R, Gratzinger D, Marinelli RJ, Lu ZS, Wong A, Levy R, Levy S, Natkunam Y. CD81 protein is expressed at high levels in normal germinal center B cells and in subtypes of human lymphomas. Hum Pathol. 2010;41:271-80.
160. Quast T, Eppler F, Semmling V, Schild C, Homsi Y, Levy S, Lang T, Kurts C, Kolanus W. CD81 is essential for the formation of membrane protrusions and regulates Rac1-activation in adhesion-dependent immune cell migration. Blood. 2011;118:1818-27.
161. Zeisel MB, Baumert TF. HCV entry and neutralizing antibodies: lessons from viral variants. Future Microbiol. 2009;4:511-7.
162. Micheloud D, Gonzalez-Nicolas J, Berenguer J, Lorente R, Miralles P, Lopez JC, Cosin J, Catalan P, Munoz-Fernandez M, Resino S. CD81 expression in peripheral blood lymphocytes before and after treatment with interferon and ribavirin in HIV/HCV coinfected patients. HIV Med. 2010;11:161-9.
163. Grigorov B, Attuil-Audenis V, Perugi F, Nedelec M, Watson S, Pique C, Darlix JL, Conjeaud H, Muriaux D. A role for CD81 on the late steps of HIV-1 replication in a chronically infected T cell line. Retrovirology. 2009;6:28.
164. Deng J, Yeung VP, Tsitoura D, DeKruyff RH, Umetsu DT, Levy S. Allergen-induced airway hyperreactivity is diminished in CD81-deficient mice. J Immunol. 2000;165:5054-61.
165. Frank MM. CD21 deficiency, complement, and the development of common variable immunodeficiency. J Allergy Clin Immunol. 2012;129:811-3.
166. Twohig JP, Pappworth IY, Sivasankar B, Kulik L, Bull M, Holers VM, Wang EC, Marchbank KJ. Defective B cell ontogeny and humoral immune response in mice prematurely expressing human complement receptor 2 (CR2, CD21) is similar to that seen in aging wild type mice. Mol Immunol. 2009;46:2002-13.
167. Rossbacher J, Haberman AM, Neschen S, Khalil A, Shlomchik MJ. Antibody-independent B cell-intrinsic and-extrinsic roles for CD21/35. Eur J Immunol. 2006;36:2384-93.
168. Fearon DT, Carroll MC. Regulation of B lymphocyte responses to foreign and self-antigens by the CD19/CD21 complex. Annu Rev Immunol. 2000;18:393-422.
169. Thiel J, Kimmig L, Salzer U, Grudzien M, Lebrecht D, Hagena T, Draeger R, Volxen N, Bergbreiter A, Jennings S, Gutenberger S, Aichem A, Illges H, Hannan JP, Kienzler AK, Rizzi M, Eibel H, Peter HH, Warnatz K, Grimbacher B, Rump JA, Schlesier M. Genetic CD21 deficiency is associated with hypogammaglobulinemia. J Allergy Clin Immunol. 2012;129:801-10 e6.
170. Asokan R, Banda NK, Szakonyi G, Chen XS, Holers VM. Human complement receptor 2 (CR2/CD21) as a receptor for DNA: implications for its roles in the immune response and the pathogenesis of systemic lupus erythematosus (SLE). Mol Immunol. 2013;53:99-110.
171. Barrington RA, Schneider TJ, Pitcher LA, Mempel TR, Ma M, Barteneva NS, Carroll MC. Uncoupling CD21 and CD19 of the B-cell coreceptor. Proc Natl Acad Sci U S A. 2009;106:14490-5.
172. Liang Y, Tedder TF. Identification of a CD20-, FcepsilonRIbeta-, and HTm4-related gene family: sixteen new MS4A family members expressed in human and mouse. Genomics. 2001;72:119-27.
173. Hamaguchi Y, Xiu Y, Komura K, Nimmerjahn F, Tedder TF. Antibody isotype-specific engagement of Fcgamma receptors regulates B lymphocyte depletion during CD20 immunotherapy. J Exp Med. 2006;203:743-53.
174. Uchida J, Lee Y, Hasegawa M, Liang Y, Bradney A, Oliver JA, Bowen K, Steeber DA, Haas KM, Poe JC, Tedder TF. Mouse CD20 expression and function. Int Immunol. 2004;16:119-29.
175. Horikawa M, Minard-Colin V, Matsushita T, Tedder TF. Regulatory B cell production of IL-10 inhibits lymphoma depletion during CD20 immunotherapy in mice. J Clin Invest. 2011;121:4268-80.
176. Kuijpers TW, Bende RJ, Baars PA, Grummels A, Derks IA, Dolman KM, Beaumont T, Tedder TF, van Noesel CJ, Eldering E, van Lier RA. CD20 deficiency in humans results in impaired T cell-independent antibody responses. J Clin Invest. 2010;120:214-22.
177. Wang JW, Howson J, Haller E, Kerr WG. Identification of a novel lipopolysaccharide-inducible gene with key features of both A kinase anchor proteins and chs1/beige proteins. J Immunol. 2001;166:4586-95.
178. Lopez-Herrera G, Tampella G, Pan-Hammarstrom Q, Herholz P, Trujillo-Vargas CM, Phadwal K, Simon AK, Moutschen M, Etzioni A, Mory A, Srugo I, Melamed D, Hultenby K, Liu C, Baronio M, Vitali M, Philippet P, Dideberg V, Aghamohammadi A, Rezaei N, Enright V, Du L, Salzer U, Eibel H, Pfeifer D, Veelken H, Stauss H, Lougaris V, Plebani A, Gertz EM, Schaffer AA, Hammarstrom L, Grimbacher B. Deleterious mutations in LRBA are associated with a syndrome of immune deficiency and autoimmunity. Am J Hum Genet. 2012;90:986-1001.
179. Dyomin VG, Chaganti SR, Dyomina K, Palanisamy N, Murty VV, Dalla-Favera R, Chaganti RS. BCL8 is a novel, evolutionarily conserved human gene family encoding proteins with presumptive protein kinase A anchoring function. Genomics. 2002;80:158-65.
180. Wang JW, Gamsby JJ, Highfill SL, Mora LB, Bloom GC, Yeatman TJ, Pan TC, Ramne AL, Chodosh LA, Cress WD, Chen J, Kerr WG. Deregulated expression of LRBA facilitates cancer cell growth. Oncogene. 2004;23:4089-97.
181. Burns SO, Zenner HL, Plagnol V, Curtis J, Mok K, Eisenhut M, Kumararatne D, Doffinger R, Thrasher AJ, Nejentsev S. LRBA gene deletion in a patient presenting with autoimmunity without hypogammaglobulinemia. J Allergy Clin Immunol. 2012;130:1428-32.
182. Alangari A, Alsultan A, Adly N, Massaad MJ, Kiani IS, Aljebreen A, Raddaoui E, Almomen AK, Al-Muhsen S, Geha RS, Alkuraya FS. LPS-responsive beige-like anchor (LRBA) gene mutation in a family with inflammatory bowel disease and combined immunodeficiency. J Allergy Clin Immunol. 2012;130:481-8 e2.
183. Dolmetsch RE, Lewis RS, Goodnow CC, Healy JI. Differential activation of transcription factors induced by Ca2+ response amplitude and duration. Nature. 1997;386:855-8.
184. Hikida M, Kurosaki T. Regulation of phospholipase C-gamma2 networks in B lymphocytes. Adv Immunol. 2005;88:73-96.
185. Ichise H, Ichise T, Ohtani O, Yoshida N. Phospholipase Cgamma2 is necessary for separation of blood and lymphatic vasculature in mice. Development. 2009;136:191-5.
186. Feske S. Calcium signalling in lymphocyte activation and disease. Nat Rev Immunol. 2007;7:690-702.
187. Feng L, Reynisdottir I, Reynisson J. The effect of PLC-gamma2 inhibitors on the growth of human tumour cells. Eur J Med Chem. 2012;54:463-9.
188. Hikida M, Casola S, Takahashi N, Kaji T, Takemori T, Rajewsky K, Kurosaki T. PLC-gamma2 is essential for formation and maintenance of memory B cells. J Exp Med. 2009;206:681-9.
189. Ombrello MJ, Remmers EF, Sun G, Freeman AF, Datta S, Torabi-Parizi P, Subramanian N, Bunney TD, Baxendale RW, Martins MS, Romberg N, Komarow H, Aksentijevich I, Kim HS, Ho J, Cruse G, Jung MY, Gilfillan AM, Metcalfe DD, Nelson C, O'Brien M, Wisch L, Stone K, Douek DC, Gandhi C, Wanderer AA, Lee H, Nelson SF, Shianna KV, Cirulli ET, Goldstein DB, Long EO, Moir S, Meffre E, Holland SM, Kastner DL, Katan M, Hoffman HM, Milner JD. Cold urticaria, immunodeficiency, and autoimmunity related to PLCG2 deletions. N Engl J Med. 2012;366:330-8.
190. Wang D, Boylin EC, Minegishi Y, Wen R, Smith CI, Ihle JN, Conley ME. Variations in the human phospholipase Cgamma2 gene in patients with B-cell defects of unknown etiology. Immunogenetics. 2001;53:550-6.
191. Mueller H, Stadtmann A, Van Aken H, Hirsch E, Wang D, Ley K, Zarbock A. Tyrosine kinase Btk regulates E-selectin-mediated integrin activation and neutrophil recruitment by controlling phospholipase C (PLC) gamma2 and PI3Kgamma pathways. Blood. 2010;115:3118-27.
192. Yasuda T, Maeda A, Kurosaki M, Tezuka T, Hironaka K, Yamamoto T, Kurosaki T. Cbl suppresses B cell receptormediated phospholipase C (PLC)-gamma2 activation by regulating B cell linker protein-PLC-gamma2 binding. J Exp Med. 2000;191:641-50.
193. Zhang B, Wu Q, Ye XF, Liu S, Lin XF, Chen MC. Roles of PLCgamma2 and PKCalpha in TPA-induced apoptosis of gastric cancer cells. World J Gastroenterol. 2003;9:2413-8.
194. Schneider P. The role of APRIL and BAFF in lymphocyte activation. Curr Opin Immunol. 2005;17:282-9.
195. He B, Xu W, Santini PA, Polydorides AD, Chiu A, Estrella J, Shan M, Chadburn A, Villanacci V, Plebani A, Knowles DM, Rescigno M, Cerutti A. Intestinal bacteria trigger T cell-independent immunoglobulin A(2) class switching by inducing epithelialcell secretion of the cytokine APRIL. Immunity. 2007;26:812-26.
196. Barroeta Seijas AB, Graziani S, Cancrini C, Finocchi A, Ferrari S, Miniero R, Conti F, Zuntini R, Chini L, Chiarello P, Bengala M, Rossi P, Moschese V, Di Matteo G. The impact of TACI mutations: from hypogammaglobulinemia in infancy to autoimmunity in adulthood. Int J Immunopathol Pharmacol. 2012;25:407-14.
197. von Bulow GU, van Deursen JM, Bram RJ. Regulation of the T-independent humoral response by TACI. Immunity. 2001;14:573-82.
198. Castigli E, Geha RS. TACI, isotype switching, CVID and IgAD. Immunol Res. 2007;38:102-11.
199. Almejun MB, Cols M, Zelazko M, Oleastro M, Cerutti A, Oppezzo P, Cunningham-Rundles C, Danielian S. A naturally occurring mutation affecting the MyD88-binding site of TNFRSF13B impairs triggering of class switch recombination. Eur J Immunol. 2013;43(3):805-14.
200. Castigli E, Wilson S, Garibyan L, Rachid R, Bonilla F, Schneider L, Morra M, Curran J, Geha R. Reexamining the role of TACI coding variants in common variable immunodeficiency and selective IgA deficiency. Nat Genet. 2007;39:430-1.
201. Rachid R, Castigli E, Geha RS, Bonilla FA. TACI mutation in common variable immunodeficiency and IgA deficiency. Curr Allergy Asthma Rep. 2006;6:357-62.
202. Salzer U, Bacchelli C, Buckridge S, Pan-Hammarstrom Q, Jennings S, Lougaris V, Bergbreiter A, Hagena T, Birmelin J, Plebani A, Webster AD, Peter HH, Suez D, Chapel H, McLean-Tooke A, Spickett GP, Anover-Sombke S, Ochs HD, Urschel S, Belohradsky BH, Ugrinovic S, Kumararatne DS, Lawrence TC, Holm AM, Franco JL, Schulze I, Schneider P, Gertz EM, Schaffer AA, Hammarstrom L, Thrasher AJ, Gaspar HB, Grimbacher B. Relevance of biallelic versus monoallelic TNFRSF13B mutations in distinguishing disease-causing from risk-increasing TNFRSF13B variants in antibody deficiency syndromes. Blood. 2009;113:1967-76.
203. Almejun MB, Sajaroff E, Galicchio M, Oleastro M, Bernasconi A, Zelazko M, Danielian S. Immunological characteristics and two novel mutations in TACI in a cohort of 28 pediatric patients with common variable immunodeficiency. J Clin Immunol. 2012;32:89-97.
204. Martinez-Gallo M, Radigan L, Almejun MB, Martinez-Pomar N, Matamoros N, Cunningham-Rundles C. TACI mutations and impaired B-cell function in subjects with CVID and healthy heterozygotes. J Allergy Clin Immunol. 2013;131(2):468-76.
205. Koopmans W, Woon ST, Brooks AE, Dunbar PR, Browett P, Ameratunga R. Clinical Variability of Family Members with the C104R Mutation in Transmembrane Activator and Calcium Modulator and Cyclophilin Ligand Interactor (TACI). J Clin Immunol. 2012.
206. Castigli E, Wilson SA, Garibyan L, Rachid R, Bonilla F, Schneider L, Geha RS. TACI is mutant in common variable immunodeficiency and IgA deficiency. Nat Genet. 2005;37:829-34.
207. Castigli E, Wilson SA, Scott S, Dedeoglu F, Xu S, Lam KP, Bram RJ, Jabara H, Geha RS. TACI and BAFF-R mediate isotype switching in B cells. J Exp Med. 2005;201:35-9.
208. Waldrep ML, Zhuang Y, Schroeder HW, Jr. Analysis of TACI mutations in CVID & RESPI patients who have inherited HLA B*44 or HLA*B8. BMC Med Genet. 2009;10:100.
209. Yang J, Pospisil R, Mage RG. Expression and localization of rabbit B-cell activating factor (BAFF) and its specific receptor BR3 in cells and tissues of the rabbit immune system. Dev Comp Immunol. 2009;33:697-708.
210. Rodig SJ, Shahsafaei A, Li B, Mackay CR, Dorfman DM. BAFF-R, the major B cell-activating factor receptor, is expressed on most mature B cells and B-cell lymphoproliferative disorders. Hum Pathol. 2005;36:1113-9.
211. McClements M, Williams S, Ball C, Bristow A, Wadhwa M, Meager A. A novel bioassay for B-cell activating factor (BAFF) based on expression of a BAFF-receptor ectodomain-tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-2 endodomain fusion receptor in human rhabdomyosarcoma cells. J Immunol Methods. 2008;337:63-70.
212. Woo YJ, Yoon BY, Jhun JY, Oh HJ, Min SW, Cho ML, Park SH, Kim HY, Min JK. Regulation of B cell activating factor (BAFF) receptor expression by NF-KappaB signaling in rheumatoid arthritis B cells. Exp Mol Med. 2011;43:350-7.
213. Hancz A, Herincs Z, Neer Z, Sarmay G, Koncz G. Integration of signals mediated by B-cell receptor, B-cell activating factor of the tumor necrosis factor family (BAFF) and Fas (CD95). Immunol Lett. 2008;116:211-7.
214. de la Torre I, Moura RA, Leandro MJ, Edwards J, Cambridge G. B-cell-activating factor receptor expression on naive and memory B cells: relationship with relapse in patients with rheumatoid arthritis following B-cell depletion therapy. Ann Rheum Dis. 2010;69:2181-8.
215. Bowers J, Tran PT, Joshi A, Liskay RM, Alani E. MSH-MLH complexes formed at a DNA mismatch are disrupted by the PCNA sliding clamp. J Mol Biol. 2001;306:957-68.
216. Tompkins JD, Wu X, Her C. MutS homologue hMSH5: role in cisplatin-induced DNA damage response. Mol Cancer. 2012;11:10.
217. Offer SM, Pan-Hammarstrom Q, Hammarstrom L, Harris RS. Unique DNA repair gene variations and potential associations with the primary antibody deficiency syndromes IgAD and CVID. PLoS One. 2010;5:e12260.
218. Bannwarth S, Figueroa A, Fragaki K, Destroismaisons L, Lacas-Gervais S, Lespinasse F, Vandenbos F, Pradelli LA, Ricci JE, Rotig A, Michiels JF, Vande Velde C, Paquis-Flucklinger V. The human MSH5 (MutSHomolog 5) protein localizes to mitochondria and protects the mitochondrial genome from oxidative damage. Mitochondrion. 2012;12:654-65.
219. Sekine H, Ferreira RC, Pan-Hammarstrom Q, Graham RR, Ziemba B, de Vries SS, Liu J, Hippen K, Koeuth T, Ortmann W, Iwahori A, Elliott MK, Offer S, Skon C, Du L, Novitzke J, Lee AT, Zhao N, Tompkins JD, Altshuler D, Gregersen PK, Cunningham-Rundles C, Harris RS, Her C, Nelson DL, Hammarstrom L, Gilkeson GS, Behrens TW. Role for Msh5 in the regulation of Ig class switch recombination. Proc Natl Acad Sci U S A. 2007;104:7193-8.